MERIT MEDICAL SYSTEMS INC (MMSI) FY2025 10-K Annual Report
MERIT MEDICAL SYSTEMS INC (MMSI) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 24, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
MERIT MEDICAL SYSTEMS INC FY2025 10-K Analysis
Business Overview
- • Core business model: design, manufacture, and sell medical devices globally with emphasis on regulatory compliance and product lifecycle management
- • Regulatory challenges heightened by EU MDR certification delays, increased costs, and discontinuation of certain products in the E.U. this fiscal year
- • Strategic shift toward development of increasingly therapeutic medical products requiring more clinical trials, raising innovation risk and regulatory complexity
- • Notable compliance and risk exposure: expanded focus on global anti-bribery laws, extensive healthcare fraud and abuse scrutiny, and evolving privacy/data protection regulations impacting operations
- • Environmental and social governance risks addressed with potential impacts from PFAS and ethylene oxide sterilization restrictions and growing corporate social responsibility requirements
Management Discussion & Analysis
- • Revenue $1.516B in 2025, up 11.8% YoY ($159.4M increase from $1.357B in 2024), driven by U.S. and EMEA demand
- • Gross margin 48.7% in 2025 vs 47.4% in 2024; net income $128.5M (8.5% margin) vs $120.4M (8.9% margin)
- • Best segment: Cardiovascular sales $1.443B (+10.9%), operating income $166.1M; Worst: Endoscopy sales $72.9M (+33.0%), operating income $18.6M
- • Increased SG&A expenses by $55.5M (13.9%) and R&D by $9.9M (11.3%) in 2025; long-term debt $747.5M, contingent liabilities $4.5M, operating leases $87.5M
- • Management highlights multi-year Continued Growth initiatives through 2026; key risks include increased effective tax rate (24.8% vs 19.8%) and foreign currency fluctuations
Risk Factors
- • Supply chain reliance on limited sterilization service providers risks production delays if any ceases operation or compliance, potentially halting sales
- • Geopolitical tensions in Ukraine, Middle East, Venezuela increasing supply interruptions, elevating cost pressures on petroleum-based materials critical to manufacturing
- • China’s Value-Based Purchasing (VBP) policy since 2022 negatively impacting pricing and revenue, with continued adverse effects expected in 2026
- • Competition from larger medical device firms and tech entrants with greater AI integration capabilities threatening market share and product relevance
- • CEO transition in Oct 2025 to Martha G. Aronson, with no key man insurance; potential disruption or loss of institutional knowledge poses material business risk
MERIT MEDICAL SYSTEMS INC FY2025 Key Financial MetricsXBRL
Revenue
$1.5B
▲ +11.8% YoY
Net Income
$128M
▲ +6.8% YoY
Gross Margin
48.7%
▲ +128bp YoY
Operating Margin
12.2%
▲ +71bp YoY
Net Margin
8.5%
▼ -40bp YoY
ROE
8.1%
▼ -62bp YoY
Total Assets
$2.7B
▲ +11.1% YoY
EPS (Diluted)
$2.13
▲ +4.9% YoY
Operating Cash Flow
$297M
▲ +34.7% YoY
Source: XBRL data from MERIT MEDICAL SYSTEMS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on MERIT MEDICAL SYSTEMS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.